Company / Cost of Revenue
Intellia Therapeutics, Inc. Cost of Revenue History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
-
FY2021
5-year range
$0 / $0
FY2018-FY2021
Trend
-
vs FY2020
Sector context
#108 of 107
Health Care
What the data says
Remained stable around $0 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top -1% in Health CareTop -1% of 107
▼
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2021 · SEC 10-K · Updated Feb 28, 2026